Protalix BioTherapeutics ... (PLX)
AMEX: PLX
· Real-Time Price · USD
2.43
0.09 (3.85%)
At close: Oct 03, 2025, 3:59 PM
2.42
-0.41%
After-hours: Oct 03, 2025, 07:36 PM EDT
3.85% (1D)
| Bid | 2.42 |
| Market Cap | 193.69M |
| Revenue (ttm) | 61.95M |
| Net Income (ttm) | 6.28M |
| EPS (ttm) | 0.09 |
| PE Ratio (ttm) | 27 |
| Forward PE | 4.25 |
| Analyst | Strong Buy |
| Dividends | n/a |
| Ask | 2.43 |
| Volume | 1,145,661 |
| Avg. Volume (20D) | 662,957 |
| Open | 2.35 |
| Previous Close | 2.34 |
| Day's Range | 2.33 - 2.52 |
| 52-Week Range | 0.99 - 3.10 |
| Beta | -0.13 |
| Ex-Dividend Date | n/a |
Analyst Forecast
According to 0 analyst ratings, the average rating for PLX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsProtalix BioTherapeutics Inc. is scheduled to release its earnings on
Nov 13, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
-40.48%
Protalix BioTherapeutics shares are trading lower ...
Unlock content with
Pro Subscription
6 months ago
+9.38%
Protalix BioTherapeutics shares are trading higher after the company reported a FY 2024 GAAP EPS beat.
1 month ago · seekingalpha.com
Protalix BioTherapeutics, Inc. (PLX) Q2 2025 Earnings Call TranscriptProtalix BioTherapeutics, Inc. (NYSE:PLX ) Q2 2025 Earnings Call August 14, 2025 8:30 AM ET Company Participants Dror Bashan - President, CEO & Director Eyal Rubin - Senior VP, CFO, Treasurer & Corpor...
1 month ago · proactiveinvestors.com
Protalix BioTherapeutics lifts revenue on strong Elfabrio demandProtalix Biotherapeutics Inc (NYSE-A:PLX) reported higher quarterly revenue and reaffirmed its long-term growth outlook on Thursday, pointing to expanding demand for its Fabry disease treatment Elfabr...
